Skip to content
CompoundSci
All peptides
Research vial labelled AOD-9604, a Fat loss and metabolic peptide studied in preclinical and clinical literature

AOD-9604

hGH fragment 176-191

The file here is mostly preclinical work plus clinic and community practice, not registrational trials.

Phase II human trials largely failed their primary endpoint. Worth knowing.

General profile

Class
Fat loss and metabolic
Evidence
Early or preclinical only
Studied dose range
300 mcg
Frequency in protocols
Daily, 5 on / 2 off
Route
Subcutaneous
Half life
~2 hours
Reconstitution
2 mL bacteriostatic water per 5 mg vial
Storage
Refrigerated, ~30 days

Timing and cycling in the literature

Usually dosed in the morning window, fasted

Daily, five days on and two off in most protocols

Studied in a fasted morning window before food. Note the phase II human trials largely missed their primary endpoint.

Reported cycle: 12 weeks on, 4 weeks off

The phase II trials dosed daily for 12 weeks. Worth remembering they largely missed their primary endpoint.

Watch for: Little in the safety record, which is the one genuinely reassuring thing about it.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Separate syringesTiming

    AOD-9604 + GLP-1 analogs

    Separate by at least a day

    Overlapping metabolic and appetite effects with heavily overlapping gastrointestinal side effects. Running them together makes it impossible to attribute nausea to either compound, which is exactly what you need to be able to do when titrating.

  • Pick oneRedundant, pick one

    AOD-9604 + Lipo-C

    Same target hit twice

    Overlapping fat-metabolism framing with no additive evidence.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how AOD-9604 fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed human efficacy trial that establishes a dose for the use people are chasing.

Open questions: Treat published dosing as observed practice, not a validated protocol.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature